0.05Open0.05Pre Close0 Volume2.73K Open Interest4.00Strike Price0.00Turnover2282.89%IV824.66%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.2329Delta0.4665Gamma8.76Leverage Ratio-0.0475Theta0.0000Rho2.04Eff Leverage0.0001Vega
Sangamo Therapeutics Stock Discussion
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results
We are proud to be showcasing our latest pipeline advances at ASGCT, including three platform presentations, reflecting our mission to develop innovative neurology genomic medicines to treat debilitating neurological diseases,” said Sandy Macrae, Chief Executive Officer of Sangamo Therapeutics. “We are particularly excited to...
No comment yet